The purpose of cardiovascular (CV) risk assessment tools is, by providing a probability of CV events over time, to segregate out populations into subgroups at varying degrees of CV risk. Those at high or very high risk may deserve particular attention in terms of preventive therapies, closer clinical follow-up, and resource allocation. In addition, risk stratification can be used to inform inclusion criteria in clinical trials. Primary prevention in atherosclerotic cardiovascular disease (ASCVD), for example, focuses on populations without clinical evidence of vascular disease (i.e. in coronary, cerebrovascular, or peripheral vascular beds). With advanced imaging tools (e.g. coronary artery calcium scans, vascular ultrasound, etc.), those with anatomical but no clinical evidence of disease [i.e. subclinical coronary artery disease (CAD)] can be further distinguished within primary prevention populations from those without such evidence (i.e. primordial prevention cohorts It is generally recognized and well established that the risk of a major adverse cardiovascular event (MACE) is much higher in those with established ASCVD (i.e. secondary prevention population). However, substantial diversity in risk among this group also exists, and distinguishing among secondary risk subgroups has attracted less attention than among primary risk populations. For example, ESC guidelines simply classify all those with established clinical ASCVD into a single (very) high risk group, 7, 8 whereas ACC/AHA secondary prevention guidelines differentiate a very high risk (VHR) from a high risk group. 9 Whether the ACC/AHA designation of VHR, based on traditional risk factors, is optimal is uncertain, and is the subject of the present study.
Summary of the current study
To provide new insight into secondary vascular risk assessment, van den Berg et al. 10 tested the predictive accuracy of the ACC/AHA VHR criteria in two separate clinical trial databases (SMART 11 and REACH 12, 13 ) and compared them against other single candidate highrisk features. The authors adapted the ACC/AHA criteria for the VHR category for their study, and defined it as ASCVD patients who also were current smokers, had diabetes, were dyslipidaemic, and/or who had a recent recurrent vascular event.
This adapted ACC/AHA grading score was applied to those with prevalent ASCVD in these two databases, and 57% and 64% in SMART and REACH, respectively, were classified as at VHR. MACE rates during follow-up were indeed slightly to moderately higher in the VHR subgroups (2.7 vs. 2.0/100 patient-years and 5.9 vs. 3.9/100 patient-years in SMART and REACH, both P < 0.001), but discrimination by the VHR criteria was poor, with C-statistics of 0.54 and 0.56 in SMART and REACH. Among single candidate factors tested, those with an estimated glomerular filtration rate (eGFR) <0.45 mL/min/ 1.73 m 2 and those with polyvascular disease showed the highest rates 
Current study perspectives
Currently, differentiation of risk among the heterogeneous population of patients with prevalent vascular disease is in its infancy. This comprehensive study of van den Berg et al. is welcomed as taking additional steps along the long pathway from probability toward certainty in secondary risk assessment. Lending validity to the study conclusions is the general consistency in findings between these two studies with differing populations, designs, and follow-up times. The generally poor discriminative ability of the adapted ACC/AHA VHR criteria in both studies provides a firm basis for re-examination and redevelopment of ASCVD secondary risk assessment tools. Identifying the candidate VHR factors (eGFR <0.45 mL/min/1.73 m 2 , polyvascular disease, and age >70 years) as useful singly and, potentially, in future multivariable risk modelling is another useful contribution.
The study has some limitations. It tests only three of many potentially additive prognostic factors not accounted for in the ACC/AHA algorithm. 9, 14 The study also did not advance the factors tested into multivariable risk prediction models, e.g. incorporating age, renal function, and polyvascular disease with the other ACC/AHA VHR factors. Sophisticated multivariable risk score algorithms are more likely than single, dichotomous variables or simple models to improve risk prediction importantly, as the authors point out. Developing advanced models should represent a high priority for future research. Also, the study appears to have tested a simplified version of the ACC/AHA VHR algorithm, which designates the presence of established ASCVD plus (i) multiple major risk factors (especially diabetes); (ii) severe and poorly controlled risk factors (especially continued cigarette smoking); (iii) multiple risk factors of the metabolic syndrome (especially high triglycerides >200 mg/dL plus non-HDL cholesterol >130 mg/dL, with low HDL cholesterol, <40 mg/ dL); and (iv) patients with acute coronary syndromes. 9 Thus, the C-statistics reported for the ACC/AHA VHR model may be underestimates. In addition, these criteria are further modified in the 2016 ACC expert consensus document, 15 as noted below.
It should also be noted that risk assessment tools generally perform well in patient populations similar to those of the risk score derivation populations. However, risk factors frequently differ in populations of differing backgrounds, including by race and ethnicity. Risk may be overestimated in healthier populations and those of higher socio-economic status, which have greater access to care, including preventive therapies. 3, 16 In contrast, risk may be underestimated in populations with major interacting co-morbidities, such as HIV. 3 Risk factors also may differ following an acute coronary event from those of chronic, stable ASCVD status. Thus, application of the results of this study and of other specific risk assessment tools in populations dissimilar to the derivation populations may be inappropriate.
Study implications
The importance of distinguishing VHR from high risk secondary subgroups in the current therapeutic environment can be challenged. That is, although the ATP-III panel guidelines provide different LDL cholesterol treatment targets for VHR patients, 17 the more recent 2013 Cholesterol Treatment Guideline did away with targets in favour of intensity of statin treatment. In this guideline, high intensity treatment is recommended for all ASCVD patients without designation of a VHR group. 2 However, targets have been added back (as an option) in the recent 2016 ACC Expert Consensus Decision Pathway on the Role of Non-statin Therapies for LDL-cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. 15 Specifically, for patients with clinical ASCVD and relevant co-morbidities, the goal is at least a 50% reduction in LDL cholesterol with statin therapy, with an option to add non-statin lipid lowering if needed to achieve an LDL cholesterol of <70 mg/dL. These high-risk co-morbidities are (re)defined as diabetes, a recent acute ASCVD event, an ASCVD event while on a statin, a baseline LDL > _190 mg/dL, an uncontrolled major risk factor, an elevated lipoprotein(a), and chronic kidney disease. For non-VHR patients with ASCVD, at least a 50% reduction in LDL cholesterol with a statin is also recommended, with an option to add non-statin therapy if an LDL cholesterol level <100 mg/dL has not been achieved. Further, the recent FOURIER trial with a drug (evolocumab) from a nonstatin class of hypolipidaemic agents [proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors] showed benefit incremental to baseline statin therapy in reducing MACE and with relative safety despite achieving a median LDL cholesterol as low as 30 mg/dL. 18 These findings reinforce the concept that 'lower is better' with an ever lower benefit 'floor'. On the other hand, the very high current cost of the marketed non-statin PCSK9 inhibitors (i.e. US$1200/month) is prohibitive for widespread use and suggests that their most costeffective application for the present will be in VHR patients. 19, 20 These very recent developments thus increase the impetus for better risk models to identify VHR subgroups.
Future needs and prospects
Beyond simply identifying VHR patient groups is the need to demonstrate clinical utility, i.e. to show that by using risk scores in decisionmaking to initiate and guide therapy, a differential impact on ASCVD outcomes can be achieved. Despite its intuitive appeal to treat high risk markers, there are numerous examples where this has not led to improved outcomes. 21 18, 27 as well as hypertension, smoking, and diabetes, in addition to the large gap in applying traditional approaches, there remain many promising opportunities for intensification of management strategies for VHR ASCVD patient groups, promises which call for better risk stratification tools.
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